Introduction

2
Typical radiotherapy regimens for patients undergoing breast conservation therapy are 45 to 3 50Gy delivered to the whole breast in daily 1.8 to 2Gy fractions over 5 or 6 weeks with or without 4 a boost dose to the excision cavity. There is increasing evidence to support the introduction of 5 strategies to tailor patients' treatment to their risk of local recurrence. Excision cavity boosts have 6 been shown to reduce the risk of recurrence and in patients of high risk of recurrence 7 simultaneous integrated boost (SIB) to the excision cavity is appropriate (1). For patients at low 8 risk of recurrence, modest dose reduction to non-target tissue away from the excision cavity is 9 expected to reduce complications without compromising tumour control because the risk of 10 recurrence is highest in the index quadrant (1). Furthermore, the observation that a modest 11 increase in fraction size accompanied by a decrease in total dose is likely to result in equivalent 12 local control (2) has led to the re-introduction of hypofractioned breast treatment. Accelerated 
20
No Action Level) that only require between 3 and 9 images for a 35 fraction treatment thus 21 decreasing both concomitant dose and workload to acceptable levels.
22
Markers implanted into the breast at lumpectomy reduce patient motion errors for the partial 23 breast or boost PTVs and hence improve accuracy of treatment. Depending on the availability of 24 imaging equipment and type of markers used, gold seeds or surgical clips, marker-based image 25 guidance may require 3D imaging which will impart higher concomitant doses.
Despite the improvements afforded by marker-based IGRT, deformation of the excision cavity is 1 of particular concern in partial breast and breast boost radiotherapy where the PTV is determined 2 by the addition of margins to the excision cavity delineated at the time of planning. We and other 3 authors (6-8 ) have reported on changes in size and shape of the excision cavity that occur during 4 treatment. These studies have measured the changes but have not investigated how these 5 changes could reduce treatment accuracy and if so how PTV margins should be adjusted 6 accordingly to account for this type of target motion, which this study attempts to do
8
The purpose of this work is to investigate the following:
9
• The effect of using established imaging verification protocols on PTV margins in a 15 10 fraction treatment regimen.
11
•
The effect of deformation on margin size
12
• The variation of PTV margin size with imaging dose 13 14
Methods
15
Fifty-three patients were recruited from four UK radiotherapy centres (centres A, B, C
16
and D) for the Gold Seed feasibility study; a full description of this study is given by 11 patient, 4 had visible or highly visible seroma (9) and two had large volume changes 1 (greater than 30% shrinkage) (6).
3
Verification Imaging behind the head. Prior to imaging, patients were set-up using orthogonal laser-6 alignment with medial and lateral skin tattoos marked at the time of planning, and any
7
isocentre shift was applied. Verification imaging was carried out for each patient to a 
24
patients using the in-house software described above. therefore the data were pooled to create a single dataset of 36 patients.
10
The following correction protocols were modelled retrospectively to the measurement 11 data from the 36 patients:
12
• No correction
13
• No Action Level (NAL) (4): mean set up error is determined from a fixed number 14 of fractions.
15
• Extended No Action Level (eNAL) (5): includes addition imaging fractions at 16 regular intervals.
17
• Daily on-line correction
18
A measurement fraction is defined as one which is used to calculate a correction value.
19
The whole patient dataset was then used to assess the effect of this correction.
21
No correction
22
No correction was applied based on the measurement data.
24
NAL Protocol
The correction value C NAL was the mean of the displacements measured at the first N m 
10
The eNAL approach started in the same way as the NAL protocol but the corrections
11
C eNAL were updated at subsequent measurement fractions. They are summarised in 
16
On line Correction
17
All measurement data were used and each measurement fraction was corrected for the 18 measured motion for that fraction.
20
Post correction, a residual error, σ r , is expected to remain due to factors such as the 21 finite accuracy with which the correction was applied, surrogate error (i.e., error in cavity position after perfect set-up to clips), and the effects of breathing variations (the internal 23 margin). From the literature (10,11) we have estimated σ r to have a random error σ r is zero. σ r will act to increase the day to day variation in post-correction patient 1 displacements. For each corrected fraction we added a correction error which was 2 randomly sampled from a normal distribution with zero mean and 2mm standard 3 deviation using Matlab (Mathworks, USA) .
5 6
The impact on margins of correction protocols was evaluated using distributions of the 
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Following the same formulism as for treatment errors the following population variables
23
were defined to describe the distribution of errors due to deformation:
• Patient-specific day-to-day deformation, ∆ p : the mean daily variation in marker 
We use the treatment errors derived using clips with positive mean displacements only, 4 mean negative displacements are set to zero.
6
Imaging Dose Data
8
Estimates for the dose delivered were collated from published data (13-15). Doses given 9 in the literature were measured using a variety of methods and measurement points.
10
MVCT doses were derived from the number of monitor units delivered (13) and related 
20
Published MV planar imaging doses were based on 5MU/image, we have adjusted the 21 dose assuming 1MU/image which was used in the Gold Seed study (9). Table 3 22 summaries the dose per image used in this study.
23
Results
2
Analysis of the uncorrected patient data (Table 4) showed that the population effective 3 systematic error (Σ mot ) was ~ 4.0 mm and the treatment execution error (σ mot ) ~ 2.7 mm.
4
The effect on Σ mot of the different correction protocols is seen in Table 5 with an on-line 5 protocol producing the greatest reduction. Off-line protocols reduced effective systematic 6 errors to between 2.0 and 1.3 mm depending upon the imaging frequency. Lower 7 effective systematic errors were obtained using the eNAL rather than the NAL protocol 8 however increasing the number of imaging days, N tot , from 5 to 8 gave a relatively small 9 reduction in Σ mot(avg) of 0.3 mm. Table 4 shows data relating to the deformation of the excision cavity. When all 12 displacements (towards and away from the COM) are considered the mean 
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way to achieve this, but PTV margins probably need to be kept very small (in the region 19 of 5 mm) to prevent excessive damage to normal tissues. In this patient group, a higher 20 imaging dose may be accepted in order to achieve safe dose escalation to excision 21 cavity. We have shown that an eNAL protocol with a total of 5 imaging sessions would enable a excision cavity margin of approximately 6mm, with an estimated total imaging 23 dose of ~0.4cGy for a kV planar imaging system or ~25cGy using MVCT (Figure 1 ). To that deformation errors are small and further studies are required to measure delineation 1 errors which are likely to be the greatest source of error.
Conclusion
2
This work has shown the relationship between PTV margin and estimated total dose 
